Aspira Women’s Health (NASDAQ:AWH) Upgraded at StockNews.com

StockNews.com upgraded shares of Aspira Women’s Health (NASDAQ:AWH) from a sell rating to a hold rating in a report issued on Wednesday.

Separately, Alliance Global Partners cut their price target on Aspira Women’s Health from $7.00 to $5.50 and set a buy rating for the company in a report on Wednesday, August 14th.

Aspira Women’s Health Price Performance

Shares of AWH opened at $0.81 on Wednesday. The firm has a market cap of $10.04 million, a P/E ratio of -0.56 and a beta of 1.48. Aspira Women’s Health has a 1 year low of $0.77 and a 1 year high of $6.01. The company has a 50 day simple moving average of $1.14 and a two-hundred day simple moving average of $2.12.

Aspira Women’s Health (NASDAQ:AWH) last posted its earnings results on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04. The company had revenue of $2.42 million for the quarter, compared to analysts’ expectations of $2.60 million. During the same period in the previous year, the business posted ($0.28) earnings per share. On average, sell-side analysts anticipate that Aspira Women’s Health will post -1.26 earnings per share for the current year.

Institutional Trading of Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. increased its stake in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 236,396 shares of the company’s stock after purchasing an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.